MARKET

AUPH

AUPH

Aurinia Pharmace
NASDAQ
15.95
+0.13
+0.82%
After Hours: 15.95 0 0.00% 19:21 12/31 EST
OPEN
15.82
PREV CLOSE
15.82
HIGH
15.98
LOW
15.80
VOLUME
667.98K
TURNOVER
--
52 WEEK HIGH
16.54
52 WEEK LOW
6.55
MARKET CAP
2.10B
P/E (TTM)
28.44
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AUPH last week (1222-1226)?
Weekly Report · 12/29/2025 09:48
Weekly Report: what happened at AUPH last week (1215-1219)?
Weekly Report · 12/22/2025 09:48
Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms
Seeking Alpha · 12/16/2025 20:57
Weekly Report: what happened at AUPH last week (1208-1212)?
Weekly Report · 12/15/2025 09:53
STEP Energy Services Ltd. Held Shareholder Meeting
Reuters · 12/12/2025 21:15
Weekly Report: what happened at AUPH last week (1201-1205)?
Weekly Report · 12/08/2025 09:52
Top SA Quant rated small-cap stocks as Russell 2000 notches a record close
Seeking Alpha · 12/04/2025 21:38
Aurinia Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners
Dow Jones · 12/03/2025 13:43
More
About AUPH
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.

Webull offers Aurinia Pharmaceuticals Inc stock information, including NASDAQ: AUPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AUPH stock methods without spending real money on the virtual paper trading platform.